Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 661 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Seizure Clear all
Completed Phase 3 Interventional Results available

Determine Safety and Efficacy of Long-term Oral Lacosamide in Patients With Partial Seizures

NCT00522275
View directory record Official record
Conditions
Partial Epilepsies
Interventions
lacosamide
Drug
Lead sponsor
UCB BIOSCIENCES, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
60
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 23, 2026, 8:34 AM EDT
Recruiting No phase listed Observational

Rapid-Response EEG in Children With Suspected Status Epilepticus

NCT06564662
View directory record Official record
Conditions
Status Epilepticus, Coma
Interventions
Rapid Response EEG
Device
Lead sponsor
Children's Hospital at Montefiore
Other
Eligibility
2 Years to 18 Years
Enrollment
60 participants
Timeline
2021 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Not applicable Interventional Results available

North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2

NCT03548779
View directory record Official record
Conditions
Epilepsy; Seizure, Neuromuscular Diseases, Brain Malformation, Intellectual Disability, Autism Spectrum Disorder, Hypotonia, Inborn Errors of Metabolism, Movement Disorders, Genetic Disease, Development Delay, Chromosome Abnormality, Hearing Loss, Dysmorphic Features, Skeletal Dysplasia, Congenital Abnormality, Microcephaly, Macrocephaly
Interventions
Pre-visit prep, usual care + exome seq
Behavioral · Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
0 Years and older
Enrollment
548 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 2 Interventional

Phase II BGG492 Capsule Extension for Partial Epilepsy

NCT01338805
View directory record Official record
Conditions
Partial Onset Seizures
Interventions
BGG492
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 66 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tallahassee, Florida • Hamilton, New Jersey • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 23, 2026, 8:34 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Not listed Phase 1Phase 2 Interventional

Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy

NCT04219995
View directory record Official record
Conditions
Intractable Epilepsy, Convulsive Seizures
Interventions
methylprednisolone sodium succinate, Placebo
Drug · Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
2 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 23, 2026, 8:34 AM EDT
Completed No phase listed Interventional Results available

Evaluation of Remote Fitting in Adult and Pediatric Users of the HiResolution Bionic Ear System

NCT05034731
View directory record Official record
Conditions
Hearing Loss, Ear Diseases, Hearing Disorders, Otolaryngological Disease
Interventions
Remote Fitting, In-Office Fitting
Device
Lead sponsor
Advanced Bionics
Industry
Eligibility
13 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures

NCT01261325
View directory record Official record
Conditions
Epilepsy
Interventions
Placebo, Brivaracetam, Antiepileptic drugs with market authorization available per country
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 80 Years
Enrollment
768 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2022 · Synced Oct 23, 2026, 8:34 AM EDT
Completed No phase listed Observational

Validation Study of the Simplified Seizure Classification Algorithm

NCT03796520
View directory record Official record
Conditions
Epilepsy
Interventions
EpiPick simplified seizure classification algorithm
Diagnostic Test
Lead sponsor
Sándor Beniczky
Other
Eligibility
10 Years to 120 Years
Enrollment
240 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures

NCT00419393
View directory record Official record
Conditions
Epilepsy
Interventions
Keppra XR (Levetiracetam XR)
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
16
States / cities
Dothan, Alabama • Northport, Alabama • Phoenix, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 23, 2026, 8:34 AM EDT
Recruiting Phase 3 Interventional

A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)

NCT05716100
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
XEN1101, Placebo
Drug
Lead sponsor
Xenon Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
19
States / cities
Little Rock, Arkansas • Downey, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Comparing Hearing Aid Fitting Methods in Blast-exposed Veterans

NCT06309264
View directory record Official record
Conditions
Auditory Diseases, Central
Interventions
Phonak Lumina P90
Device
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 60 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Loma Linda, California • Sepulveda, California • West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 4 Interventional Results available

Dexmedetomidine and Propofol for Pediatric MRI Sedation

NCT03513757
View directory record Official record
Conditions
Headache, Tumor, Seizure Disorder, Neurofibromatoses, Hydrocephalus, Abdominal Neoplasm, Spine Deformity
Interventions
propofol, Dexmedetomidine, Glycopyrrolate, Lidocaine 1% Injectable Solution, Nitrous Oxide, Sevoflurane
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
12 Months to 60 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome

NCT02823145
View directory record Official record
Conditions
Dravet Syndrome
Interventions
ZX008 (Fenfluramine Hydrochloride)
Drug
Lead sponsor
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.
Industry
Eligibility
2 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
24
States / cities
Phoenix, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 2Phase 3 Interventional

Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)

NCT06999902
View directory record Official record
Conditions
Focal Seizure
Interventions
20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo
Drug
Lead sponsor
Praxis Precision Medicines
Industry
Eligibility
18 Years to 75 Years
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Phoenix, Arizona • Loma Linda, California • DeLand, Florida + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 4 Interventional

Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug

NCT00043901
View directory record Official record
Conditions
Epilepsy, Tonic-Clonic
Interventions
lamotrigine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
2 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
80
States / cities
Alabaster, Alabama • Mobile, Alabama • Northport, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 23, 2026, 8:34 AM EDT
Completed No phase listed Observational

Transcranial Magnetic Stimulation for the Treatment of Poorly Controlled Partial Epilepsy

NCT00001666
View directory record Official record
Conditions
Partial Epilepsy, Seizures
Interventions
Cadwell High-Speed Magnetoelectric Stimulator, Magpro High-Speed Magnetoelectric Stimulator
Device
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Not applicable Interventional

Contact Lens Trial Fitting Experience

NCT07600645
View directory record Official record
Conditions
Presbyopia
Interventions
Lens A ( stenfilcon A )
Device
Lead sponsor
CooperVision International Limited (CVIL)
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Bellaire, Texas • Corpus Christi, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Terminated Phase 4 Interventional Results available

Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines

NCT02090998
View directory record Official record
Conditions
Transformed Migraine, Chronic Daily Headache
Interventions
SPG Block with 5% Lidocaine gel, Amitriptyline
Procedure · Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 8:34 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters

NCT01529034
View directory record Official record
Conditions
Epilepsy
Interventions
USL261
Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
12 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 23, 2026, 8:34 AM EDT
Not listed Not applicable Interventional

Study to Validate Novel Seizure-Detection Algorithm

NCT04291716
View directory record Official record
Conditions
Seizures, Motor, Seizures, Seizure Disorder, Epilepsy, Epileptic Seizures, Epileptic
Interventions
Motor Seizure Detection Algorithm (mSDA)
Device
Lead sponsor
Overwatch Digital Health
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional

Internet Administration of the Modified Atkins Diet for Adults With Intractable Epilepsy

NCT00436631
View directory record Official record
Conditions
Epilepsy
Interventions
Dietary management of seizures
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 2, 2015 · Synced Oct 23, 2026, 8:34 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures

NCT01142193
View directory record Official record
Conditions
Epilepsy
Interventions
USL255, Placebo
Drug
Lead sponsor
Upsher-Smith Laboratories
Industry
Eligibility
18 Years to 75 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
19
States / cities
Phoenix, Arizona • Ventura, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 22, 2014 · Synced Oct 23, 2026, 8:34 AM EDT
Recruiting Phase 2 Interventional

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

NCT07219407
View directory record Official record
Conditions
Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure
Interventions
RAP-219
Drug
Lead sponsor
Rapport Therapeutics Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Boise, Idaho • Rochester, Minnesota • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 23, 2026, 8:34 AM EDT